Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Abbott laboratories | History Defined

A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

MarketBeat

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

Barchart

Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound?

Barchart

3 High Dividend Growth Kings for Generations of Income That Are Still Rated ‘Buy’

These 3 Dividend Kings combine steady businesses, rising dividends, and solid upside potential for long-term income investors.

Barchart

Do Wall Street Analysts Like Abbott Laboratories Stock?

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?

Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Abbott’s January Pullback a Good Time to Buy?

Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow.

MarketBeat

Stocks Supported by Easing Geopolitical Tensions and Solid US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.59%. March E-mini S&P futures (ESH26 ) are up +0.52%, and March E-mini Nasdaq futures...

Barchart

2 Healthcare Names That Could Get a Big Boost From Earnings

Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish.

MarketBeat

What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

Barchart

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Benzinga

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Barchart

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Barchart

5 Dividend Aristocrats Proving That Reliability Still Pays in 2025

These five companies offer stability in terms of growth and income.

MarketBeat

Abbott Laboratories' October Price Plunge Is a Signal to Buy

Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.

Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.

Benzinga

Bank Earnings Lift Wall Street, Gold Hits $4,200: What's Moving Markets Wednesday?

Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectations for further Federal Reserve rate cuts — keeping trade concerns sidelined for now.

Barchart

Stocks Climb on Strong Q3 Earnings and Easing Trade Concerns

The S&P 500 Index ($SPX ) (SPY ) today is up +1.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.40%. December E-mini S&P futures (ESZ25 ) are up +0.95%, and December E-mini Nasdaq futures...

Barchart

Stocks Supported by Strong Q3 Earnings Results

The S&P 500 Index ($SPX ) (SPY ) today is up +0.73%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.81%. December E-mini S&P futures (ESZ25 ) are up +0.73%, and December E-mini Nasdaq futures...

Benzinga

Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectations

Abbott Laboratories (NYSE:ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.

Benzinga

Stock Market Today: S&P 500, Nasdaq Futures Rise— Bank Of America, Morgan Stanley, Abbott Earnings In Focus (UPDATED)

Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the latest economic releases were updated in the story.

Benzinga

Abbott Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.